ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO535

AKI Evaluation and Mortality Risk on Mexican Patients

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Villalvazo, Priscila Berenice, IMSS, Zapopan, Jaliscco, Mexico
  • Flores Fonseca, Milagros Melissa, Centro Medico Nacional de Occidente, Guadalajara, Mexico
  • Rodriguez, Viridiana, Instituto Mexicano Del Seguro Social, Guadalajara, Mexico
  • Gomez-Navarro, Benjamin, IMSS, HECMNO, Zapopan, Jalisco, Mexico
  • Andrade-Sierra, Jorge, Universidad de Guadalajara, Cucs, Guadalajara, Jalisco Mexico, Mexico

AKI prevalence in Mexico is unknown and mortality rates are estimated 16 – 18%, its presence increases the risk of death in critically ill patients and is associated with high morbidity and mortality. In Mexico, limited data including early RRT, AKI biomarkers, furosemide response and risks factors of AKI progression, remains AKI treatment controversial. This study aimed to evaluate characteristics and risk factors of AKI and predict RRT and renal function recovery.


We analyze a single center AKI cohort of 112 Mexican patients. Serum creatinine assay was done to diagnose AKI. Demographics, clinical and biochemical profiles, risk factors for AKI and RRT prescription was assessed and reported during diagnosis and discharge. Outcome measures were renal recovery, mortality and causes of death.


Mean age was 56.81 ± 18.38 years, 73% on AKI stage 3, mixed causes (60%) and pre-renal AKI (26%) were the most frequent forms. Main etiologies were cardiovascular disease (30%) and sepsis (24%). Of 112 patients, 49% initiate RRT and 55% had renal recovery. Global mortality rate was 48% mainly due to cardiovascular disease. We observed significant differences between (p=0.05) in serum creatinine admission OR=01.65 (1.47-1.83) and fluid balance OR=1.56 (1.45-1.69) as risk factors for RRT and furosemide response OR 9.16 (4.03-39.96) as renal recovery factor.


This was the first study that evaluate AKI risk factors, allowing RRT therapy and enhance renal recovery. Our findings support the furosemide stress test response strongly allows the adequate risk stratification, and can be used for early RRT initiation and might prolong time to renal recovery. Further studies are needed to determine if at the time of admission measurement of AKI biomarkers, may significantly improve the ability to predict hard outcomes (RRT, renal recovery and death).


  • Government Support - Non-U.S.